PT-141
Also called Bremelanotide
What to know about PT-141
PT-141 is bremelanotide, a melanocortin-receptor agonist studied for centrally mediated sexual-desire outcomes rather than vascular effects alone.
- How it may work
- It activates melanocortin receptors in the central nervous system. The exact pathway responsible for measured sexual-desire changes is not fully resolved.
- What research found
- Two phase 3 trials randomized 1,267 premenopausal women and found statistically significant improvements in desire and related-distress measures versus placebo, with modest absolute changes.
- What is not settled
- Nausea, flushing, and headache were common in trials. The licensed label also addresses transient blood-pressure increases, focal hyperpigmentation, and use limits.
- Research and product status
- Bremelanotide has a licensed U.S. product for a specific population and use. Research vials are not equivalent to that product.
Research reference
- Research amount range
- 0.5–2 mg per administration — not a starting amount
- Reference frequency
- Once a week — catalogue input, not a personal schedule
- Evidence route
- Subcutaneous in the cited evidence; formulation matters. Sites and rotation
- Model accumulation timescale
- ~14 hours — about five half-lives with regular repeated exposure; not time to a result
- Storage
- Storage and in-use limits depend on the exact formulation and packaging. A compound name alone cannot establish temperature, diluent, or shelf life. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
When results may show
- When change was measured
- The licensed bremelanotide label uses an as-needed dose at least 45 minutes before anticipated activity, while noting that the duration and optimal window are not fully characterized.
- When to assess
- The label provides an eight-week reassessment point for its licensed population and use. Results from that standardized autoinjector should not be assumed for other formulations or populations.
- Conditions and limitations
- The licensed evidence does not require food, a special time of day, or another compound. It does require the labelled population, subcutaneous autoinjector, cardiovascular screening, and dosing limits.
- When to stop
- The label says to discontinue after eight weeks if symptoms have not improved, and to consider discontinuation for hyperpigmentation or persistent or severe nausea. Its other warning signs also take precedence.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Combination evidence and cautions
What is known and unknown about PT-141 alongside other compounds or medicines.
Key properties
- Formula
- C50H68N14O10
- Mol. weight
- 1,025.2 Da
- CAS
- 189691-06-3
- PubChem CID
- 9941379
External references
Vial arithmetic
Published research contexts for PT-141 describe 0.5–2 mg per administration. Descriptive only, not a recommendation.
Research schedule reference
Reported schedule context for PT-141; not a plan to start or adjust personal use.
These are commonly-discussed research protocols shared for educational reference. Study amounts apply to the source's population, formulation, and oversight; they do not establish personal suitability. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| As neededA melanocortin agonist used episodically, not on a standing daily schedule. Nausea is dose-limiting. | 0.5–2 mg | Up to once in 24 h, a few hours before | SubQ |
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 0.96× single dose
- Time to steady state
- 14hours
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Bremelanotide (Vyleesi) programA melanocortin-receptor agonist studied for sexual-desire indications.